Table 3 Correlation between clinicopathological features and β-tubulin class III, GSTP1, and TLE3 expression in 52 locally advanced or metastatic breast cancer
Parameters | β-tubulin class III | p value | GSTP1 | p value | TLE3 | p value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Positive (n = 21) | Negative (n = 31) | Positive (n = 24) | Negative (n = 28) | Positive (n = 24) | Negative (n = 28) | |||||
HR and HER2 status | ||||||||||
TNBC | 7 (33.3%) | 15 (48.4%) | 0.281 | 13 (54.2%) | 9 (32.1%) | 0.109 | 14 (58.3%) | 8 (28.6%) | 0.030 | |
non-TNBC | 14 (66.7%) | 16 (51.6%) | 11 (45.8%) | 19 (67.9%) | 10 (41.7%) | 20 (71.4%) | ||||
Age at operation | ||||||||||
≤63 | 9 (42.9%) | 17 (54.8%) | 0.397 | 10 (41.7%) | 16 (57.1%) | 0.266 | 15 (62.5%) | 11 (39.3%) | 0.095 | |
>63 | 12 (57.1%) | 14 (45.2%) | 14 (58.3%) | 12 (42.9%) | 9 (37.5%) | 17 (60.7%) | ||||
Degree of progress | ||||||||||
Locally advanced | 6 (28.6%) | 7 (22.6%) | 0.624 | 4 (16.7%) | 9 (32.1%) | 0.168 | 6 (25.0%) | 7 (25.0%) | 1.000 | |
Visceral metastases | 15 (71.4%) | 24 (77.4%) | 20 (83.3%) | 19 (67.9%) | 18 (75.0%) | 21 (75.0%) | ||||
Life threatening condition | ||||||||||
non- Life threatening | 16 (76.2%) | 22 (71.0%) | 0.677 | 15 (62.5%) | 23 (82.1%) | 0.111 | 15 (62.5%) | 23 (82.1%) | 0.111 | |
Life threatening | 5 (23.8%) | 9 (29.0%) | 9 (37.5%) | 5 (17.9%) | 9 (37.5%) | 5 (17.9%) | ||||
Nuclear grade | ||||||||||
1, 2 | 13 (61.9%) | 20 (64.5%) | 0.848 | 14 (58.3%) | 19 (67.9%) | 0.477 | 13 (54.2%) | 20 (71.4%) | 0.198 | |
3 | 8 (38.1%) | 11 (35.5%) | 10 (41.7%) | 9 (32.1%) | 11 (45.8%) | 8 (28.6%) | ||||
Estrogen receptor | ||||||||||
Negative | 8 (38.1%) | 17 (54.8%) | 0.236 | 14 (58.3%) | 11 (39.3%) | 0.171 | 15 (62.5%) | 10 (35.7%) | 0.054 | |
Positive | 13 (61.9%) | 14 (45.2%) | 10 (41.7%) | 17 (60.7%) | 9 (37.5%) | 18 (64.3%) | ||||
Progesterone receptor | ||||||||||
Negative | 12 (57.1%) | 20 (64.5%) | 16 (66.7%) | 16 (57.1%) | 18 (75.0%) | 14 (50.0%) | ||||
Positive | 9 (42.9%) | 11 (35.5%) | 0.592 | 8 (35.3%) | 12 (42.9%) | 0.482 | 6 (25.0%) | 14 (50.0%) | 0.065 | |
HER2 | ||||||||||
Negative | 18 (85.7%) | 29 (93.5%) | 0.317 | 23 (95.8%) | 24 (85.7%) | 0.227 | 23 (95.8%) | 24 (85.7%) | 0.227 | |
Positive | 3 (14.3%) | 2 (6.5%) | 1 (4.2%) | 4 (14.3%) | 1 (4.2%) | 4 (14.3%) | ||||
Ki67 | ||||||||||
Negative | 11 (52.4%) | 15 (48.4%) | 0.777 | 14 (58.3%) | 12 (42.9%) | 0.266 | 12 (50.0%) | 14 (50.0%) | 1.000 | |
Positive | 10 (47.6%) | 16 (51.6%) | 10 (41.7%) | 16 (57.1%) | 12 (50.0%) | 14 (50.0%) | ||||